Archive for May 6th, 2010
Dr Reddy’s posts Rs 1.7 billion net profits in Q4 2009-2010; US sales drop
India's second largest pharma company Dr Reddy's Laboratories reported a net profit of 1.7 billion rupees ($37 million) in the quarter to March, its fiscal fourth quarter, compared with a loss of 9.8 billion last year.
Hepatitis c virus could turn resistant against Vertex’ teleprevir
Vertex Pharmaceuticals Inc.’s experimental hepatitis C drug telaprevir could become ineffective as the virus strains turn resistant to the drug.
India makes registration of hospitals and clinics compulsory
Registration of all clinical establishments made mandatory in India as part of its effort to bring in uniformity in the healthcare delivery sector.
Par to market Glenmark’s ezetimibe (Zetia) generic in US
Glenmark has entered into an exclusive licensing agreement with Par Pharmaceutical to market ezetimibe 10 mg tablets in US.
Novartis promotes imatinib (Gleevec) for unapproved dosages to treat gastrointestinal tumours (GIST), myelogenous leukemia (CML): Warns US FDA
US FDA has warned Novartis against promoting the use of imatinib (Gleevec) in gastrointestinal stromal tumours (GIST) and chronic myelogenous leukemia (CML) in unapproved dosage strengths.
Stromal cell-derived factor-1 drug NOX -A12 can treat various cancers: Noxxon
NOX-A12, an experimental stromal cell-derived factor-1 to treat various cancers developed by Noxxon, has successfully completed first-in-man studies, the company announced.
